Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma

Conditions

• Childhood Burkitt Lymphoma
• Childhood Central Nervous System Choriocarcinoma
• Childhood Central Nervous System Germ Cell Tumor
• Childhood Central Nervous System Germinoma
• Childhood Central Nervous System Mixed Germ Cell Tumor
• Childhood Central Nervous System Teratoma
• Childhood Central Nervous System Yolk Sac Tumor
• Childhood Choroid Plexus Tumor
• Childhood Craniopharyngioma
• Childhood Diffuse Large Cell Lymphoma
• Childhood Immunoblastic Large Cell Lymphoma
• Childhood Medulloepithelioma
• Childhood Meningioma
• Childhood Mixed Glioma
• Childhood Nasal Type Extranodal NK/T-cell Lymphoma
• Childhood Oligodendroglioma
• Recurrent Childhood Anaplastic Large Cell Lymphoma
• Recurrent Childhood Brain Stem Glioma
• Recurrent Childhood Central Nervous System Embryonal Tumor
• Recurrent Childhood Cerebellar Astrocytoma
• Recurrent Childhood Cerebral Astrocytoma
• Recurrent Childhood Ependymoma
• Recurrent Childhood Grade III Lymphomatoid Granulomatosis
• Recurrent Childhood Large Cell Lymphoma
• Recurrent Childhood Lymphoblastic Lymphoma
• Recurrent Childhood Malignant Germ Cell Tumor
• Recurrent Childhood Medulloblastoma
• Recurrent Childhood Pineoblastoma
• Recurrent Childhood Small Noncleaved Cell Lymphoma
• Recurrent Childhood Subependymal Giant Cell Astrocytoma
• Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor
• Recurrent Childhood Visual Pathway and Hypothalamic Glioma
• Recurrent Childhood Visual Pathway Glioma
• Recurrent/Refractory Childhood Hodgkin Lymphoma
• Unspecified Childhood Solid Tumor, Protocol Specific

Interventions

• DRUG: vorinostat
• DRUG: bortezomib
• OTHER: pharmacological study
• OTHER: laboratory biomarker analysis

Sponsor

National Cancer Institute (NCI)